OGN — Organon & Co.

Organon (OGN) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $6.2 billion for 2025, down 3% year-over-year (YoY).
• Adjusted EBITDA: $1.9 billion, flat compared to 2024.
• Fourth Quarter Revenue: $1.57 billion, down 8% YoY at constant currency.
• Net Loss: $205 million for Q4 2025, compared to net income of $109 million in Q4 2024. This includes a noncash goodwill impairment of $301 million.
• Non-GAAP Adjusted Net Income: $165 million ($0.63 per diluted share) for Q4 2025, down from $235 million ($0.90 per diluted share) in Q4 2024.
• Free Cash Flow: $960 million for 2025, consistent with prior year.

2. Strategic Updates and Business Highlights

• Biosimilars: Strong performance driven by Hadlima, which grew 61% YoY. New launches contributed positively, including denosumab biosimilars.
• Nexplanon: FDA approved an sNDA to extend the duration from 3 to 5 years, potentially broadening the market.
• Cost Management: Achieved over $200 million in cost savings in 2025, maintaining adjusted EBITDA margins despite gross margin degradation.
• Divestiture: Sold the Jada system for approximately $390 million, which will aid in debt reduction efforts.
• Dividend Policy: Lowered dividend payout ratio to focus on debt reduction.

3. Forward Guidance and Outlook

• 2026 Revenue and EBITDA Guidance: Expecting approximately $6.2 billion in revenue and $1.9 billion in adjusted EBITDA, consistent with 2025.
• Nexplanon Sales: Anticipated to be flat YoY due to the transition to a 5-year label and ongoing U.S. market challenges.
• Cost Structure: Continued focus on managing operating expenses, with expectations for adjusted gross margin to decline by 75 to 100 basis points in 2026.

4. Bad News, Challenges, or Points of Concern

• Declining Metrics: Revenue and net income have decreased YoY, with significant losses attributed to goodwill impairment.
• Nexplanon Challenges: Experienced a 20% decline in sales in Q4, impacted by U.S. policy changes and a shift in market dynamics.
• Competitive Pressures: The fertility business faced a 6% decline in Q4, particularly in China, and is expected to encounter increased competition in the U.S.
• Pricing Pressures: Anticipated headwinds from pricing adjustments and loss of exclusivity (LOE) for several products, including Atozet.
• Regulatory Risks: Concerns regarding the impact of REMS (Risk Evaluation and Mitigation Strategy) on Nexplanon sales and potential bottlenecks.

5. Notable Q&A Insights

• CEO Search: The Board is conducting a robust search for a permanent CEO, but no updates were provided.
• Biosimilars Strategy: Management views recent FDA guidance as incremental rather than transformative, focusing on strategic partnerships for growth.
• Nexplanon Volume Outlook: Anticipated headwinds from the transition to a 5-year label may persist into 2027, but management remains optimistic about long-term growth potential.
• Operating Costs: Management emphasized the need to balance cost reductions with investments in revenue-generating opportunities, particularly in light of declining gross margins.

This summary encapsulates the key aspects of Organon's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, and challenges faced by the company.